The FDA has missed the deadline for making a key decision regarding a Novavax (NVAX.US) Covid-19 vaccine, days after the Food and Drug Administration’s vaccine chief was pushed out. Novavax’s application needed more data and was unlikely to be approved soon - was said by people familiar with a matter, citted by WSJ.
This information is seriously damaging the sentiment around the company and is undermining its current ability to maintain its business system. The shares are losing over 1.5%, although at one point the declines were as high as 4%.
Source: xStation
TSMC delivers a record quarter. AI is driving results and reshaping the entire cycle
⬆️Chart of the Day - US500 Rises to All-Time Highs! (16.04.2026)
Daily summary: The market pauses at the top
AllBirds: From sneakers to AI, can It work?